Navigation Links
YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB
Date:6/23/2009

than 3,500 patients reported as having been treated with nimotuzumab worldwide to date, no Grade IV incidents of radiation dermatitis have been described, severe rash has not been observed and reports of the other severe side-effects that are typical of EGFR-targeting molecules have been rare. Nimotuzumab is licensed to YM's majority-owned subsidiary, CIMYM BioSciences Inc., by CIMAB S.A., and was developed at the Center of Molecular Immunology. YM is developing AeroLEF for the treatment of moderate to severe acute pain. The product is differentiated from other approaches using fentanyl because patients can individually control the analgesia required for their differing intensities of pain. AeroLEF met all endpoints in a randomized Phase II trial and is currently being prepared for late-stage development internationally.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that nimotuzumab will continue to demonstrate a competitive safety profile in ongoing and future clinical trials; that AeroLEF(R) will continue to generate positive efficacy and safety data in future clinical trials; and that YM and its various
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... July 6, 2015 ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") ... agreement with Novella Clinical (Novella), to conduct ... with newly diagnosed glioblastoma. Novella is a full-service, global ... small to mid-sized oncology companies. The ICT-107 phase 3 ... US, Europe and ...
(Date:7/3/2015)... WIEN , July 3, ... Tiedemiehet voivat hakea verkossa osoitteessa  ... for Open Innovation in Science" ... Ludwig Boltzmann Gesellschaftin (LBG) tekemän, ... tutkimuksen mukaan terveystieteiden kaksi suurinta ...
(Date:7/3/2015)... July 3, 2015 ... september 2015 på  http://www.openinnovationinscience.at till det ... Science" som hålls i Wien ... undersökning med internationella forskare och vetenskapsmän som ... hälsovetenskapens två största utmaningar bristen på incitament ...
(Date:7/3/2015)... WIEN , July 3, 2015 /PRNewswire/ ... indtil den 22. september 2015 på  http://www.openinnovationinscience.at ... in Science", der finder sted i ... en nylig undersøgelse af internationale forskere og ... er de to største udfordringer for sundhedsvidenskaben ...
Breaking Biology Technology:ImmunoCellular Therapeutics Establishes Agreement with Novella Clinical to Conduct ICT-107 Phase 3 Registration Trial in Glioblastoma 2Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 2Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 3Lansering av världens första program för öppen innovation för att utbilda forskare 2Lansering av världens första program för öppen innovation för att utbilda forskare 3Lancering af verdens første åbne innovationsprogram til uddannelse af forskere 2Lancering af verdens første åbne innovationsprogram til uddannelse af forskere 3
... declaration that America is "addicted to oil" was paired with ... in the nations grain belt. Its unclear whether Wisconsin can ... but the broader idea of using genetically engineered plants to ... boon to the states rural economy. , ,The war ...
... Wis. John Hawks has a cardinal rule with ... it down." , ,The University of Wisconsin-Madison anthropologist practices what ... down, but share it with the world via academic weblog. ... solved Hawks' practical academic needs and also happened to evolve ...
... IT consultancy with a significant Wisconsin presence, has been ... , ,Howard Blietz and Eric Wasowicz, Greenbrier & Russel's ... roles. A Fujitsu company statement said that most of ... in their current roles for now to maintain continuity ...
Cached Biology Technology:Wisconsins promising bio-refining future wont run on ethanol alone 2Wisconsins promising bio-refining future wont run on ethanol alone 3Anthropology professor's blog raises public interest 2Anthropology professor's blog raises public interest 3
(Date:6/18/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... growing mobile commerce market announces that its Wocket® smart wallet ... on the Mark", scheduled to air on WABC Radio (am770) ... th . The broadcast air- time for ... 8:00pm EST. NXT-ID, Inc.,s CEO Gino Pereira will ...
(Date:6/17/2015)... GERMANTOWN, Maryland , and HILDEN, Germany ... (NASDAQ: QGEN ; Frankfurt Prime Standard: QIA) today launched ... DNA evidence in forensic laboratories in the United ... integrated solution to simultaneously analyze multiple key genomic markers (short ... Investigator ® Quality Sensor to evaluate the quality of ...
(Date:6/17/2015)... 17, 2015  Crossmatch™, a leading provider of ... U.are.U ® 4500 fingerprint readers have been ... Inc., a San Jose, CA ... security, improve accountability and reduce fraud at the ... identity confirmation for employee sign in and transaction ...
Breaking Biology News(10 mins):NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 4QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 5Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 2Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 3
... are parasitic plants that suck water, nutrients and information from ... the University of California, Davis, have now shown that they ... where the parasite taps into the host. "We think ... Sinha, professor of plant biology at UC Davis, who led ...
... the top of a tube of potato chips, it can ... researchers may have found a novel way to help: edible ... part of an experiment carried out on two groups of ... clips in class, researchers from Cornell,s Food and Brand Lab ...
... team is developing virtual models of human knee joints ... react to heavy loads virtual models that someday ... the aging process or by debilitating diseases, such as ... is leveraging the powerful computing systems of the Ohio ...
Cached Biology News:Hitting back at 'wiretapping' parasite 2Researchers study knee stress at tissue, cellular levels 2
Mouse monoclonal [CLB-SW16 (formerly 708)] to CD42d (rating: ****) ( Abpromise for all tested applications). entrezGeneID: 2814 SwissProtID: P40197...
Mouse monoclonal [7C6] to Bcr-abl ( Abpromise for all tested applications). SwissProtID: P11274...
Affinity Purified Rabbit Anti-mouse sRANKL Biotinylated Polyclonal Antibody...
Rabbit polyclonal to FOXJ2 ( Abpromise for all tested applications). entrezGeneID: 55810 SwissProtID: Q9P0K8...
Biology Products: